Initial toxicity, QoL outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated vs. standard fractionated PT for low-risk prostate cancer
08/02/2018
/
Publications
/
Hypofractionation
Quality of life
A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and...
Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.
08/09/2018
/
Publications
/
Quality of life
A study by the Seattle group analyzed 231 patients of localized prostate cancer treated with protons. Median follow-up was 1.7 years. Grade 3 toxicity was seen...
Finding Value for Protons: The Case of Prostate Cancer?
05/04/2018
/
Publications
/
Dosimetry
Quality of life
A review by UPenn examined the dosimetric data and clinical outcome reports. Clinical studies largely suggest no difference in urinary side effects or erectile...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.